Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.
Study Name: Ralinepag 301
Study Objective: A Phase 3, randomized, double-blind, placebo-controlled study to
evaluate the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background oral therapy in subjects with World
Health Organization (WHO) Group 1 pulmonary hypertension (ADVANCE Outcomes)
Key Inclusion Criteria:
Key Exclusion Criteria:
3 or more of following:
2. Evidence of > mild lung disease on PFT w/i 6M
3. Evidence of thromboembolic disease
4. Severe chronic liver disease
PI: Evelyn Horn, MD
RC: Astrid Carmona, 212 746 2623